{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:07:01Z","timestamp":1768259221926,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.cllc.2012.09.001","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T19:00:35Z","timestamp":1351191635000},"page":"254-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Yaopeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2012.09.001_bib1","first-page":"225","article-title":"Cancer statistics","volume":"2009","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2012.09.001_bib2","author":"Ferlay"},{"key":"10.1016\/j.cllc.2012.09.001_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdq189","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"D'Addario","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2012.09.001_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLC.2009.n.030","article-title":"Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer","volume":"10","author":"Hirsh","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2012.09.001_bib7","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.cllc.2012.09.001_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2012.09.001_bib9","doi-asserted-by":"crossref","unstructured":"Logman JFS, Botteman MF, Kaura S. Cost-effectiveness assessment of zoledronic acid (ZOL) relative to placebo (PBO) in the treatment of lung cancer patients with skeletal metastases in five European countries. Paper presented at: 12th Annual European Congress International Society for Pharmacoeconomics and Outcomes Research (ISPOR): Health Care Decision Making in Europe: From Patients to Populations. October 24-27, 2009; Paris, France.","DOI":"10.1016\/S1098-3015(10)74329-1"},{"key":"10.1016\/j.cllc.2012.09.001_bib10","first-page":"879","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cllc.2012.09.001_bib11","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1200\/jco.2007.25.18_suppl.6617","article-title":"Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: the case of the United Kingdom (UK)","volume":"25","author":"Botteman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clinthera.2011.04.002","article-title":"Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom","volume":"33","author":"Joshi","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.cllc.2012.09.001_bib13","first-page":"844","article-title":"Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration resistant prostate cancer, lung cancer, or other solid tumors","volume":"28","author":"Tchekmedyian","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cllc.2012.09.001_bib14","unstructured":"Hatoum HT, Sin S, Lipton A, et al. Persistency on monthly zoledronic acid impacts risk and frequency of skeletal complications and follow-up duration in lung cancer patients. Paper presented at the 13th World Congress on Lung Cancer. July 31-August 1, 2009; San Francisco, CA."},{"key":"10.1016\/j.cllc.2012.09.001_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminoncol.2007.10.006","article-title":"Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease","volume":"34","author":"Saad","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2407-6-60","article-title":"Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells","volume":"6","author":"Goffinet","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2012.09.001_bib18","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2174\/092986707781389600","article-title":"Zoledronic acid\u2014a multiplicity of anti-cancer action","volume":"14","author":"Yuasa","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cllc.2012.09.001_bib19","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and other solid tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2009.08.020","article-title":"Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates","volume":"67","author":"Langer","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2012.09.001_bib21","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2009.10.003","article-title":"Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain","volume":"40","author":"Paes","year":"2010","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cllc.2012.09.001_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0022-5347(17)59002-3","article-title":"Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report","volume":"116","author":"Firusian","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.cllc.2012.09.001_bib25","first-page":"2054","article-title":"Strontium-89 for the palliation of bone pain due to metastatic disease","volume":"35","author":"Taylor","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cllc.2012.09.001_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/187152007781058596","article-title":"Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases","volume":"7","author":"Lam","year":"2007","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.cllc.2012.09.001_bib27","first-page":"549","article-title":"Strontium-89 therapy: measurement of absorbed dose to skeletal metastases","volume":"29","author":"Blake","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cllc.2012.09.001_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bone.2005.12.004","article-title":"Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases","volume":"39","author":"Storto","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.cllc.2012.09.001_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00003072-200206000-00008","article-title":"Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP","volume":"27","author":"Marcus","year":"2002","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cllc.2012.09.001_bib30","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1200\/JCO.2006.06.1952","article-title":"Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study","volume":"24","author":"Papotti","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s002590100533","article-title":"A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer","volume":"28","author":"Dafermou","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.cllc.2012.09.001_bib32","first-page":"1347","article-title":"Effectiveness of the radioactive strontium (89Sr) chloride agent, SMS.2P for pain palliation in patients with metastatic bone tumor in phase III multicenter clinical trial. [in Japanese]","volume":"33","author":"Kimura","year":"1996","journal-title":"Kaku Igaku"},{"key":"10.1016\/j.cllc.2012.09.001_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.radonc.2005.03.003","article-title":"Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review","volume":"75","author":"Bauman","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","article-title":"Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer","volume":"76","author":"Saad","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.cllc.2012.09.001_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib36","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","article-title":"Potential anticancer properties of bisphophonates","volume":"37","author":"Neville-Webbe","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2012.09.001_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3816\/CLC.2011.n.003","article-title":"The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer","volume":"12","author":"Mahtani","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2012.09.001_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1040-8428(11)70006-3","article-title":"Anticancer evidence for zoledronic acid across the cancer continuum","volume":"77","author":"Costa","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2012.09.001_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(11)00032-1","article-title":"Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum","volume":"77","author":"Terpos","year":"2011","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730412001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730412001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:03:36Z","timestamp":1761505416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730412001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1525730412001982"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2012.09.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non\u2013Small-Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2012.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}